Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Safety, Tolerability, and Immunogenicity of Vaxneuvance (V114) in Healthy Japanese Infants
jRCT2080224598Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal disease (3 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability of V114 (SC and IM) compared with PCV13 (SC) and Immunogenicity of V114 (SC and IM) compared with PCV13 (SC). Started Mar 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT2080224598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224598.